CytomX Therapeutics, Inc. (NASDAQ:CTMX) Receives $6.67 Consensus Target Price from Analysts

Shares of CytomX Therapeutics, Inc. (NASDAQ:CTMX) have been assigned an average recommendation of “Moderate Buy” from the eight analysts that are covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and seven have assigned a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $8.1429.

A number of equities research analysts have commented on CTMX shares. HC Wainwright boosted their target price on shares of CytomX Therapeutics from $5.00 to $10.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. Wall Street Zen downgraded shares of CytomX Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, November 8th. Wedbush reiterated an “outperform” rating and set a $6.00 target price on shares of CytomX Therapeutics in a research report on Friday, November 7th. Guggenheim started coverage on CytomX Therapeutics in a research note on Tuesday. They set a “buy” rating and a $10.00 price target for the company. Finally, Piper Sandler boosted their target price on shares of CytomX Therapeutics from $6.50 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of CTMX. Orbimed Advisors LLC purchased a new position in CytomX Therapeutics during the 2nd quarter valued at $19,208,000. Commodore Capital LP purchased a new stake in shares of CytomX Therapeutics during the 2nd quarter worth $17,462,000. Perceptive Advisors LLC purchased a new stake in shares of CytomX Therapeutics during the second quarter valued at about $15,876,000. Franklin Resources Inc. acquired a new stake in CytomX Therapeutics in the second quarter valued at approximately $13,096,000. Finally, Vivo Capital LLC acquired a new stake in shares of CytomX Therapeutics in the 2nd quarter worth $13,096,000. Hedge funds and other institutional investors own 67.77% of the company’s stock.

CytomX Therapeutics Stock Down 2.9%

CTMX opened at $5.56 on Tuesday. CytomX Therapeutics has a 52 week low of $0.40 and a 52 week high of $6.15. The stock has a market cap of $941.18 million, a PE ratio of 13.89 and a beta of 2.42. The business has a 50 day moving average of $4.26 and a 200-day moving average of $3.25.

CytomX Therapeutics (NASDAQ:CTMX) last issued its quarterly earnings results on Thursday, November 6th. The biotechnology company reported ($0.09) EPS for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.05). CytomX Therapeutics had a return on equity of 44.49% and a net margin of 24.66%.The company had revenue of $5.96 million during the quarter, compared to the consensus estimate of $11.50 million. Equities analysts anticipate that CytomX Therapeutics will post -0.05 EPS for the current year.

CytomX Therapeutics Company Profile

CytomX Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of next-generation therapeutics based on its proprietary Probody® platform. The company engineers masked antibody prodrugs that remain inactive in healthy tissue but are selectively activated in the tumor microenvironment. This approach is designed to enhance the safety and tolerability of antibody-based therapies, particularly those targeting immuno-oncology pathways.

At the core of CytomX’s pipeline is Pacmilimab (CX-072), an anti–PD-L1 Probody therapeutic currently undergoing clinical evaluation for multiple solid tumor indications.